Explore the words cloud of the BITFORM project. It provides you a very rough idea of what is the project "BITFORM" about.
The following table provides information about the project.
UNIVERSIDAD POLITECNICA DE MADRID
|Coordinator Country||Spain [ES]|
|Total cost||245˙732 €|
|EC max contribution||245˙732 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2019-10-01 to 2022-09-30|
Take a look of project's partnership.
|1||UNIVERSIDAD POLITECNICA DE MADRID||ES (MADRID)||coordinator||245˙732.00|
|2||The Regents of the University of California Los Angeles||US (Los Angeles)||partner||0.00|
In this project I will develop an integrated multi-module platform in which a breast cancer ecosystem-on-a-chip (BCE-on-a-chip) bioreactor module, connected to an optical biosensing module based on multiplexed Resonant Nanopillars (R-NPs) transducers, will be developed for biomarkers and anti-breast cancer drug real-time monitoring. Currently attrition rates in clinical trials for new anti-cancer drugs and personalized treatments are higher than all other therapeutic areas. Mainly due to the great reliability on conventional 2D and 3D scaffolds in-vitro culture methodologies in preclinical studies. Those cell-based models are limited by theirâ€¨ inability to conserve the patient tumor features and do not accurately show drug response, observed later in clinical trials. Due to the increasing number of cancer diagnoses, an engineered system that allows an accurate prediction of patient tumor response to anti-cancer drug, is urgently needed. In Bitform Project I will develop a BCE-on-a-chip bioreactor that intends to conserve the cancer tissue characteristics with high reliability. Breast cancer cell secreted biomarkers will be monitored in real-time with a multiplexed biosensing module based on R-NPs. In order to assess the capability of Bitform platform, an anti-cancer drug demonstrator (Paclitaxel) will be tested. By delivering Paclitaxel to the BCE-on-a-chip, monitoring of different cell secreted target biomarkers will permit to evaluate the effect of this drug, and thus to demonstrate the performance of the platform. The Bitform platform will be suitable for different organ-on-chip culture models and biomolecules monitoring secreted by the cells. This will lead to a new methodology for testing anti-cancer therapies on-a-chip. This is a relevant milestone to study the further potential of the Bitform Platform in personalized medicine, which can have a transformative impact not only on the outcome but also on the costs of treatments by avoiding expensive failures.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITFORM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BITFORM" are provided by the European Opendata Portal: CORDIS opendata.
Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological ResponsesRead More
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More
Quantum Topological PolaritonicsRead More